Cumberland Pharmaceuticals Achieves Remarkable 23% Revenue Surge in First Half of 2025 Cumberland Pharmaceuticals Inc. reports a stunning 23% revenue growth year-to-date, driven by FDA-approved product sales, showcasing their strong market presence.

Cumberland Pharmaceuticals Achieves Remarkable 23% Revenue Surge in First Half of 2025 #United_States #Nashville #Cumberland_Pharmaceuticals #Vibativ #Caldolor

Caldolor® Proves to be a Safe and Effective Opioid-Sparing Option for Pain Management in Seniors Cumberland Pharmaceuticals reveals new data demonstrating that Caldolor® provides effective pain management while reducing opioid consumption in older adults, enhancing recovery outcomes.

Caldolor® Proves to be a Safe and Effective Opioid-Sparing Option for Pain Management in Seniors #USA #Nashville #Pain_Management #Cumberland_Pharmaceuticals #Caldolor